FDA Peptide Policy: What BPC-157 Compounding Means in Australia

The US Department of Health and Human Services (HHS) has issued a draft policy letting pharmacies compound six peptides, including BPC-157, without fear of FDA enforcement. It is not an approval and it does not apply in Australia.

What does the HHS policy say?

AJMC reported on 29 October 2026 that the draft covers BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. It applies to state-licensed pharmacies, federal facilities and licensed physicians, and stays in place until the FDA addresses the peptides in a final rule. Comments close two weeks after the Federal Register notice, scheduled for 30 October.

What conditions does it set?

• •Bulk material from an FDA-registered manufacturer, with a certificate of analysis covering identity, purity, potency and contaminants such as endotoxins
• •Serious adverse events reported to FDA's MedWatch
• •One active ingredient per product, labelled as compounded
• •A patient-specific prescription

HHS says it wants a "more controlled alternative" to research-use-only peptides from foreign manufacturers.

What did FDA scientists say?

Agency reviewers recommended against listing each of the six. FDA briefing materials called the available studies, including five on BPC-157, "short, small, and insufficient to establish safety or effectiveness". An advisory committee overruled that advice in July.

What does it mean in Australia?

Nothing changes. Australia has no equivalent of the US compounding framework, and BPC-157 and TB-500 remain unapproved therapeutic goods under the Therapeutic Goods Act 1989. See the guide to the six peptides.

Research use only

Peptide Labs supplies research peptides strictly for in-vitro laboratory use, not for human or animal use. This article reports public news and gives no use or dosing guidance.

Sources

• •AJMC, 29 October 2026